SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.

Start Date01 Oct 2025

Sponsor / Collaborator

Beth Israel Deaconess Medical Center, Inc.

NCT06062810

/ Active, not recruitingPhase 2/3

Explore the Relationship Between Single Nucleotide Polymorphisms and Raloxifene Response and Toxicity in Patients With Breast Cancer LCIS

Explore the relationship between drug target ER gene single nucleotide polymorphisms and Raloxifene therapeutic effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes.
Explore the relationship between drug target UGT gene single nucleotide polymorphisms and Raloxifene side-effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes.

Start Date21 Jun 2025

Sponsor / Collaborator

Medicine Invention Design, Inc.

NCT06055179

/ RecruitingNot ApplicableIIT

Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang (XCHT) Against Irinotecan-Induced Gut Toxicities(Clinical Study Part:Randomized Controlled Trial)

Randomized double-blind placebo-controlled trial (RCT) study, to determine the impact of XCHT on irinotecan-induced severe delayed-onset diarrhea (SDOD), and to determine the feasibility of using plasma raloxifene-4'-glucuronide as a probe for intestinal UGT activity.

Start Date08 Mar 2024

Sponsor / Collaborator

Guangzhou University of Chinese Medicine

[+1]

100 Clinical Results associated with Raloxifene Hydrochloride

100 Translational Medicine associated with Raloxifene Hydrochloride

100 Patents (Medical) associated with Raloxifene Hydrochloride

4,825

Literatures (Medical) associated with Raloxifene Hydrochloride

01 Jan 2026·TALANTA

Engineering Fe-doped carbon-based nanozyme from novel source for chemiluminescence/colorimetric dual-mode microplate sensing of the anticancer drug raloxifene in different matrices

Article

Author: Abd-AlGhafar, Walaa Nabil ; Tolba, Manar M ; Shabana, Rasha Abo ; El-Shaheny, Rania

A novel carbon-based nanozyme has been designed and synthesized via upcycling expired pharmaceutical; gabapentin (GABA) into Fe, N, S-doped carbon dots within 3 min of microwave irradiation. The engineered nanozyme exhibits unique dual oxidase/peroxidase-mimicking activities. Thus, a dual-mode sensing microplate-based platform was introduced. The new nanozyme presents peroxidase-like properties that can catalyze H₂O₂ to produce ¹O₂ species, triggering long-lasting glow-type chemiluminescence (CL) of luminol. The oxidase-mimic activity of the nanozyme was evidenced using 3,3',5,5'-tetramethylbenzidine (TMB) as substrate in the absence of H₂O₂, which turned blue (oxTMB) in acidic pH (λ_max = 655 nm). This innovative dual-signal platform was utilized for the analysis of raloxifene (RLX), which is an estrogen receptor modulator used as an anticancer and anti-osteoporosis drug, in multiple matrices. RLX acts as an inhibitor of nanozyme action, resulting in quenching of the CL signal and fading of the oxTMB blue color. Consequently, the nano-sensing strategy showed excellent ultrasensitive linear ranges of 10.0-2000.0 and 10.0-200.0 ng mL^-1 with remarkably low detection limits of 3.03 and 3.30 ng mL^-1 for the CL and colorimetric methods, respectively. The designed nanosensor was successfully applied for RLX assay in various matrices, involving hospital effluent, tap and river waters, pharmaceuticals, and human urine, with excellent % recovery from 95.20 to 102.10 % in CL and 96.46-104.63 % in colorimetry. The dual-mode signal system performs self-inspection by comparing the detection outcomes of each mode; thus, it grants sensitivity, accuracy, and fidelity. Notably, this strategy eliminates the need for pyrolysis at high temperature, lengthy multistep, and high energy, which distinguishes it from traditional procedures for nanozyme synthesis. It offers an effective new avenue for furnishing sensing platforms from waste used for clinical diagnosis, environmental pollution control, and pharmaceutical monitoring.

01 Oct 2025·REPRODUCTIVE TOXICOLOGY

Human umbilical cord mesenchymal stem cell-derived exosomes repair raloxifene-induced damage in endometrial stromal cells via autophagy activation

Article

Author: Chen, Shiling ; Cao, Lixin ; Mi, Xuguang ; Lin, Xiuying ; Sun, Munan ; Wu, Mengxue ; Liu, Lei ; Fang, Yanqiu ; Lu, Xiaodan ; Niu, Chunxue ; Wang, Qilai ; Wei, HaiFeng ; Fu, Jianhua

Estrogen plays a central role in promoting endometrial thickening during the menstrual cycle. In patients with a thin endometrium, endometrial cells exhibit reduced sensitivity to estrogen, contributing to female infertility. We established an endometrial stromal cell damage model using the estrogen antagonist raloxifene (RAL) and investigated the role and underlying mechanism of human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-EXO) in repairing RAL-induced damage in human endometrial stromal cells (hEndoSCs). In this study, hEndoSCs were treated with RAL and subsequently cultured with hUCMSC-EXO. The results showed that hUCMSC-EXO restored the proliferative capacity of hEndoSCs, decreased endogenous reactive oxygen species production, and increased mitochondrial membrane potential. Mechanistic analysis indicated that hUCMSC-EXO activated intracellular autophagy, and that autophagy inhibition reversed the protective effects of hUCMSC-EXO on hEndoSCs. These findings suggest that hUCMSC-EXO may ameliorate endometrial injury associated with estrogen insensitivity.

01 Sep 2025·Endocrine Practice

Dental Implant Failure and Medication-Related Osteonecrosis of the Jaw Related to Dental Implants in Patients Taking Antiresorptive Therapy for Osteoporosis: A Systematic Review and Meta-Analysis

Review

Author: Ruggiero, Salvatore ; Tetradis, Sotirios ; Alnajimi, Rasha ; Morrison, Archibald ; Guyatt, Gordon ; Ali, Dalal S ; Khan, Aliya A ; Mirza, Reza ; El Rabbany, Mohamed

OBJECTIVES:

To inform the 2024 International Task Force on Osteonecrosis of the Jaw update, we conducted a systematic review and meta-analysis evaluating dental implant failure and medication-related osteonecrosis of the jaw (MRONJ) related to antiresorptive therapy for osteoporosis.

METHODS:

We searched 5 databases (1946-2024) for interventional and noninterventional studies reporting rates of dental implant failure or osteonecrosis in those with osteoporosis or osteopenia. Two reviewers independently screened all titles, abstracts, and full texts. Risk of bias was assessed using the modified Ottawa-Newcastle scale, and the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation.

RESULTS:

We found 793 unique citations. Nine studies (n = 655) were included in the implant failure analysis. Random-effects meta-analysis revealed wide confidence intervals (CIs) for implant failure among those exposed to antiresorptives (relative risk, 0.82; 95% CI, 0.52-1.28; P = .38, very low certainty). Sensitivity analysis at the level of implant suggested that antiresorptives reduce implant failure (relative risk, 0.53; 95% CI, 0.34-0.81; P = .003, very low certainty). We identified 186 cases of MRONJ in implant recipients. The pooled rate of MRONJ following implantation in those exposed to antiresorptive therapy was 0.5% pooled from 21 cohorts. A single report of risk-adjusted MRONJ found that bisphosphonates increased MRONJ by 3 cases per 1000 patients (adjusted hazard ratio, 4.09; 95% CI, 2.75-6.09; P < .001, moderate certainty).

CONCLUSIONS:

The low-certainty evidence suggests that antiresorptive therapy for osteoporosis reduces dental implant failure. Bisphosphonates are associated with MRONJ in patients with osteoporosis receiving dental implants with moderate certainty.

News (Medical) associated with Raloxifene Hydrochloride

10 Sep 2024

·www.drugs.com

Review Weighs Treatments for Genitourinary Symptoms of Menopause

TUESDAY, Sept. 10, 2024 -- Vaginal estrogen, vaginal dehydroepiandrosterone (DHEA), oral ospemifene, and vaginal moisturizers may be beneficial for some genitourinary symptoms of menopause (GSM), according to a review published online Sept. 10 in the Annals of Internal Medicine . Elisheva R. Danan, M.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues examined the effectiveness and harms of vaginal estrogen, nonestrogen hormone therapies, and vaginal moisturizers for treatment of GSM in a systematic review of randomized controlled trials (RCTs). A total of 46 RCTs assessing vaginal estrogen, nonestrogen hormones, vaginal moisturizers, or multiple interventions were identified from 11,993 citations. The researchers found that vaginal estrogen may improve vulvovaginal dryness, dyspareunia , the most bothersome symptom, and treatment satisfaction compared with placebo or no treatment. Vaginal DHEA may improve dryness, dyspareunia, and distress, bother, or interference from genitourinary symptoms compared with placebo; oral ospemifene may improve dryness, dyspareunia, and treatment satisfaction; and dryness may also be improved by vaginal moisturizers (all low certainty of evidence [COE]). No benefit or uncertain effects (low and very low COE, respectively) may be provided by vaginal testosterone, systemic DHEA, vaginal oxytocin, and oral raloxifene or bazedoxifene. Reporting was limited by studies of short duration that were insufficiently powered to assess infrequent serious harms. "Future studies would be strengthened by standard definitions of symptoms and uniform diagnostic criteria for GSM, a common set of validated outcome measures and reporting standards, and attention to clinically relevant patient populations and intervention comparisons," the authors write.

Clinical Result

24 May 2023

·www.biospace.com

New Data Reveal Role of SARS-Cov-2 Spike Protein in Covid-19 Associated Coagulopathy

Unprecedented comprehension of the interaction between Spike and the Human Estrogen Receptor Alfa provides insights for a new generation of anti SARS-CoV-2 and pan-Coronavirus vaccines Italian and US researchers have revealed how the SARS-CoV-2 Spike protein interacts with human Estrogen Receptor-α (ERα) leading to severe coagulopathy observed in COVID-19 patients. The new data - published in Nature’s Signal Transduction and Targeted Therapy - shows that point mutations in the sequence of SARS-CoV-2 Spike (S)-protein eliminate its pro-coagulation effect without compromising immunogenicity. The findings provide actionable insights for designing vaccines lacking of estrogen-receptor mediated side effects for all coronavirus strains and other viral infections. MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)-- Dompé farmaceutici announced today new peer-reviewed data demonstrating that small changes in the SARS-CoV-2 Spike (S)-protein sequence can eliminate its effect in inducing coagulation1. The tendency for the Spike protein to stimulate inflammatory and coagulation has been implicated in coagulopathy observed in the lungs, heart and kidneys of COVID-19 patients with a similar and extremely rare effects observed in a minority of patients who received COVID-19 vaccines. This press release features multimedia. View the full release here: Framework Dompé farmaceutici Biotech production (Photo: Business Wire) Data stemmed from the EXSCALATE supercomputing calculation predicted a potential function of Spike (S) as a co-factor for human ERα nuclear signalling. This interaction is mediated by a nuclear receptor co-regulator (NRC) LXD-like motif present on the viral protein S2 subunit, and the activation function 2 (AF-2) region on ERα2. This work builds on other recent studies3,4 showing that coagulopathy is clearly associated with the interaction of the SARS-CoV-2 Spike (S) protein with the human Erα. While circulating estrogens play a protective role by regulating the immune response to infection, modulation of ERα signalling in SARS-CoV-2-infected lung tissue stimulates proinflammatory signals leading to hypertrophy, vasoconstriction, and vessel obstruction. In the new article the scientists of the italo-american collaboration (encompassing Centro Cardiologico Monzino in Italy and the National Institute on Drug Abuse and the Johns Hopkins School of Medicine in the US) demonstrated that the interaction between the Spike protein and ERα leads to an increase in tissue factor (TF) and the overall pro-coagulation activity in two human endothelial cell lines. The results were further validated by overexpressing S-protein in mice. This pro-coagulative function of Spike in vitro and in vivo, was abolished or strongly reduced by the variants of the Spike proteins carrying mutations in the interaction domain with ERα (as predicted by EXSCALATE). “The value and benefits of vaccines in countering the COVID-19 pandemic remain unquestionable and overwhelming compared to the risks associated with infection from SARS-CoV-2” underscores Maurizio Pesce, a research Group Leader at the Monzino Cardiology Center in Milan, Italy, and initiator of the study in 2021 together with the leading Silvia Barbieri, another research Group Leader at Monzino, “We hope that our findings will be considered in the development of the next generation of vaccines reducing the residual side effects and risks. Our data also unravel a new function of the viral protein in direct regulation of thrombosis associated factors. This has general implications not only for COVID-19, but for other viral infections altering the coagulation pro patients”. “This continuing research is critical to understand the pathogenetic mechanisms associated with SARS-CoV2 infection and causal mechanisms of some rare COVID-19 vaccine side effects,” says Dompé farmaceutici Chief Scientific Officer Marcello Allegretti “Ongoing expanding data is revealing a well-conserved region with the same characteristics of the LXD-like motif present on the viral protein S2 subunit, also in other Coronaviruses. This evidence could open new scenarios in ‘pan-Coronavirus’ vaccination. We are excited to identify a path toward further refinement strategies to enable even more powerful benefits through future vaccination and booster initiatives”. ____________________________________________________________________________________ About Dompé Dompé is a private, rapidly scaling international biopharmaceutical company founded in Milan, Italy, with a 130-year legacy of medical innovation. The R&D department of the company is anchored by EXSCALATE, a structure-based virtual screening platform developed in-house that leverages one of the most powerful supercomputing and artificial intelligence platforms in the world. Today, Dompé employs more than 800 employees worldwide and maintains a US commercial operations hub in the San Francisco Bay Area as well as an R&D presence in Boston. Forward Looking Statements This press release refers to certain information that may not coincide with expected future results. Dompé firmly believes in the soundness and reasonableness of the concepts expressed. However, some of the information is subject to a certain degree of indetermination in relation to its research and development activities and the necessary verifications to be performed by regulatory bodies. Therefore, as of today, Dompé cannot guarantee that the expected results will be consistent with the information provided above. 1. SS Barbieri et al. Relevance of the viral Spike protein/cellular Estrogen Receptor-α interaction for endothelial-based coagulopathy induced by SARS-CoV-2 - Signal Transduction and Targeted Therapy - 2. Allegretti, M. et al. Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 370 infection. Cell Death Differ. 29, 156-166 (2022). 371 - 3. Wilcox et al. Sex Differences in Thrombosis and Mortality in Patients Hospitalized for COVID-19, Am J Cardiol. 2022 May 1; 170: 112–117 - 4. Science Advances - The SARS-CoV-2 spike protein binds and modulates estrogen receptors - eadd4150 (2022) 30 November 2022 -

Vaccine

24 May 2023

·www.dompe.com

New Data Reveal Role of SARS-Cov-2 Spike protein in Covid-19 associated coagulopathy

Italian and US researchers have revealed how the SARS-CoV-2 Spike protein interacts with human Estrogen Receptor-α (ERα) leading to severe coagulopathy observed in COVID-19 patients. Italian and US researchers have revealed how the SARS-CoV-2 Spike protein interacts with human Estrogen Receptor-α (ERα) leading to severe coagulopathy observed in COVID-19 patients. The new data - published in Nature’s Signal Transduction and Targeted Therapy - shows that point mutations in the sequence of SARS-CoV-2 Spike (S)-protein eliminate its pro-coagulation effect without compromising immunogenicity. The findings provide actionable insights for designing vaccines lacking of estrogen-receptor mediated side effects for all coronavirus strains and other viral infections. The new data - published in Nature’s Signal Transduction and Targeted Therapy - shows that point mutations in the sequence of SARS-CoV-2 Spike (S)-protein eliminate its pro-coagulation effect without compromising immunogenicity. The findings provide actionable insights for designing vaccines lacking of estrogen-receptor mediated side effects for all coronavirus strains and other viral infections. MILAN, Italy and SAN MATEO, Calif. | 22 May, 2023 - Dompé farmaceutici announced today new peer-reviewed data demonstrating that small changes in the SARS-CoV-2 Spike (S)-protein sequence can eliminate its effect in inducing coagulation [1]. The tendency for the Spike protein to stimulate inflammatory and coagulation has been implicated in coagulopathy observed in the lungs, heart and kidneys of COVID-19 patients with a similar and extremely rare effects observed in a minority of patients who received COVID-19 vaccines. Data stemmed from the EXSCALATE supercomputing calculation predicted a potential function of Spike (S) as a co-factor for human ERα nuclear signalling. This interaction is mediated by a nuclear receptor co-regulator (NRC) LXD-like motif present on the viral protein S2 subunit, and the activation function 2 (AF-2) region on ERα [2]. This work builds on other recent studies [3], [4] showing that coagulopathy is clearly associated with the interaction of the SARS-CoV-2 Spike (S) protein with the human Erα. While circulating estrogens play a protective role by regulating the immune response to infection, modulation of ERα signalling in SARS-CoV-2-infected lung tissue stimulates proinflammatory signals leading to hypertrophy, vasoconstriction, and vessel obstruction. In the new article the scientists of the italo-american collaboration (encompassing Centro Cardiologico Monzino in Italy and the National Institute on Drug Abuse and the Johns Hopkins School of Medicine in the US) demonstrated that the interaction between the Spike protein and ERα leads to an increase in tissue factor (TF) and the overall pro-coagulation activity in two human endothelial cell lines. The results were further validated by overexpressing S-protein in mice. This pro-coagulative function of Spike in vitro and in vivo, was abolished or strongly reduced by the variants of the Spike proteins carrying mutations in the interaction domain with ERα (as predicted by EXSCALATE). “The value and benefits of vaccines in countering the COVID-19 pandemic remain unquestionable and overwhelming compared to the risks associated with infection from SARS-CoV-2” underscores Maurizio Pesce, a research Group Leader at the Monzino Cardiology Center in Milan, Italy, and initiator of the study in 2021 together with the leading Silvia Barbieri, another research Group Leader at Monzino, “We hope that our findings will be considered in the development of the next generation of vaccines reducing the residual side effects and risks. Our data also unravel a new function of the viral protein in direct regulation of thrombosis associated factors. This has general implications not only for COVID-19, but for other viral infections altering the coagulation profile of patients”. “This continuing research is critical to understand the pathogenetic mechanisms associated with SARS-CoV2 infection and causal mechanisms of some rare COVID-19 vaccine side effects,” says Dompé farmaceutici Chief Scientific Officer Marcello Allegretti “Ongoing expanding data is revealing a well-conserved region with the same characteristics of the LXD-like motif present on the viral protein S2 subunit, also in other Coronaviruses. This evidence could open new scenarios in ‘pan-Coronavirus’ vaccination. We are excited to identify a path toward further refinement strategies to enable even more powerful benefits through future vaccination and booster initiatives”. [1] SS Barbieri et al. Relevance of the viral Spike protein/cellular Estrogen Receptor-α interaction for endothelial-based coagulopathy induced by SARS-CoV-2 - Signal Transduction and Targeted Therapy [2] Allegretti, M. et al. Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 370 infection. Cell Death Differ. 29, 156-166 (2022). 371 [3] Wilcox et al. Sex Differences in Thrombosis and Mortality in Patients Hospitalized for COVID-19, Am J Cardiol. 2022 May 1; 170: 112–117 [4] Science Advances - The SARS-CoV-2 spike protein binds and modulates estrogen receptors - eadd4150 (2022) 30 November 2022

Vaccine

100 Deals associated with Raloxifene Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02217	Raloxifene Hydrochloride	G03XC01	DB00481

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	United States	Eli Lilly & Co.	13 Sep 2007
Osteoporosis, Postmenopausal	United States	Eli Lilly & Co.	09 Dec 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	France	Dompe Farmaceutici SpA	22 Jan 2021
COVID-19	Phase 3	Italy	Dompe Farmaceutici SpA	22 Jan 2021
COVID-19	Phase 3	Spain	Dompe Farmaceutici SpA	22 Jan 2021
Cardiovascular Diseases	Phase 3	United States	Eli Lilly & Co.	01 Jun 1998
Coronary Disease	Phase 3	United States	Eli Lilly & Co.	01 Jun 1998
Invasive Mammary Carcinoma	Phase 3	United States	Eli Lilly & Co.	01 Jun 1998
Hemorrhagic Fever, Ebola	Phase 2	Italy	Dompe Farmaceutici SpA	30 Jan 2022
Hepatitis B	Phase 2	Italy	Dompe Farmaceutici SpA	30 Jan 2022
Hepatitis C, Chronic	Phase 2	Italy	Dompe Farmaceutici SpA	30 Jan 2022
Zika Virus Infection	Phase 2	Italy	Dompe Farmaceutici SpA	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05172050 (CTgov)	Phase 2/3	COVID-19	61	Raloxifene (Raloxifene 60 mg)	lwnwxhjfas = naznaiuixq xiwnghlsqd (hryiaggwvj, iogusiuaox - suiqgatxnu) View more	-	14 Dec 2023
				Raloxifene (Raloxifene 120 mg)	lwnwxhjfas = mgsrrcxuck xiwnghlsqd (hryiaggwvj, jhzpcabfhd - zpwializgg) View more
ERA2020	Not Applicable	Chronic Kidney Diseases	39,128	Osteoporosis medications (bisphosphonates, raloxifene, teriparatide, or denosumab)	bbczehpukx(vzjmbjipkb) = rtpchpweqj wcglvfxfyo (hvllfxyroi ) View more	Negative	06 Jun 2020
2020 ARVO Annual Meeting (ARVO2020)	Phase 2	Brain Injuries, Traumatic	-	Raloxifene 5 mg/kg	uzmlcnxjkd(antbsmpkbg) = reduced or eliminated ljencvlrnj (hrmmjmtkgx ) View more	Positive	01 Jun 2020
				Raloxifene 10 mg/kg
NCT00687102 (Co-STAR, CTgov)	Phase 3	Cognition	1,498	tamoxifen (Star Participants Assigned to Tamoxifen)	kjbvnfoigg(dqwctshuvi) = tbznyjpkzk ynolycrybe (rrqlgkoumy, 0.34) View more	-	23 Jan 2018
				raloxifene (Star Participants Assigned to Raloxifene)	kjbvnfoigg(dqwctshuvi) = qcgvodfrjj ynolycrybe (rrqlgkoumy, 0.32) View more
NCT01280305 (Pubmed \| J Clin Psychiatry)	Phase 3	Schizoaffective disorder \| Schizophrenia	200	Raloxifene 120 mg/d plus antipsychotics	pfdmlsajru(kswsjigney): P-Value = < .001	Negative	01 Jul 2017
				Placebo plus antipsychotics
NCT00427700 (CTgov)	Phase 3	Polycystic Ovary Syndrome	82	Clomiphene citrate (Clomiphene)	cwhzcccuiv = hmvcdwfxyr vshyrcyrnp (xzrqsosmtr, rbwtujavmo - ulajysoqou) View more	-	06 Oct 2016
				raloxifene (Raloxifene)	cwhzcccuiv = mprnauscgh vshyrcyrnp (xzrqsosmtr, dfzzlpwauf - scvmlmfgfg) View more
NCT00030147 (CTgov)	Phase 4	Depressive Disorder	65	Placebo skin patch and placebo tablets (Placebo)	wwviwcpkbk(mtpjqxrfgk) = bfvddgbrdy byhdbrrcug (yeldnkoywn, 9) View more	-	05 Sep 2016
				Raloxifene (Raloxifene)	wwviwcpkbk(mtpjqxrfgk) = ommqxocrnf byhdbrrcug (yeldnkoywn, 7.9) View more
NCT00361543 (Pubmed \| JAMA Psychiatry)	Phase 4	Schizophrenia, Treatment-Resistant	56	Raloxifene hydrochloride	ysvmhfybsn(pyldedjbjk): β = -1.92 View more	Positive	01 Sep 2016
				Placebo
NCT00368459 (CTgov)	Phase 2	Alzheimer Disease	42	raloxifene (Raloxifene)	tmwuogmvyd(hrkkgsawwl) = joxgerdkko rzphdmuvwa (fvnrktelvg, 5.8) View more	-	02 Apr 2015
				Placebo (Placebo)	tmwuogmvyd(hrkkgsawwl) = tsuiueqiww rzphdmuvwa (fvnrktelvg, 8.0) View more
NCT01166958 (CTgov)	Phase 4	Osteoporosis	26	Teriparatide (Daily Teriparatide (Forteo))	ftkqfyxwmh(zgshpoueex) = kfcnsslfgq qyeuqnsukc (ahrsfvxddd, inaldrneif - uotzggfbal) View more	-	22 Sep 2014
				Raloxifene+Teriparatide (Monthly Cycles of Teriparatide Followed by Raloxifene)	ftkqfyxwmh(zgshpoueex) = jkcxwwxzcw qyeuqnsukc (ahrsfvxddd, pzuqienofg - hvxqyvcpmn) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis